Genomtec S.A.
GMT.WA · WSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.39 | -1.65 | -0.16 | 0.32 |
| FCF Yield | -2.12% | -3.20% | -2.87% | 0.84% |
| EV / EBITDA | -53.55 | -38.09 | -42.10 | -78.30 |
| Quality | ||||
| ROIC | -17.55% | -23.68% | -15.60% | -14.17% |
| Gross Margin | -143,250.00% | -51,083.33% | -21,840.00% | 0.00% |
| Cash Conversion Ratio | 0.85 | 0.95 | 1.05 | -0.49 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -62.63% | 87.02% |
| Free Cash Flow Growth | 31.21% | 3.99% | -481.48% | 112.01% |
| Safety | ||||
| Net Debt / EBITDA | 2.85 | 3.26 | 4.48 | 3.08 |
| Interest Coverage | -61.29 | -29.88 | -65.89 | -37.02 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 18,669.02 | 11,839.53 | 19,521.51 | 146.63 |